Want to see TSE:NRX full AI Analyst Report?
Top Page
NurExone Biologic
(NRX)
Select Model
Select Model
Rating:51Neutral
Price Target:
C$0.65
▲(30.60% Upside)
Action:Reiterated
Date:09/24/26
The score is held back primarily by weak financial performance (no revenue, persistent losses, and ongoing cash burn with shrinking equity). Technical indicators provide some support with a mildly positive trend and neutral momentum, while valuation is inconclusive due to a negative P/E and no dividend yield data.
Positive Factors
Low Financial Leverage
Very low leverage limits interest and refinancing pressure while preserving flexibility to fund research and development. For an early-stage biotechnology company, the modest debt burden reduces fixed financial obligations, although it does not eliminate the need for future capital.
Negative Factors
No Commercial Revenue
The absence of revenue means NurExone has not yet demonstrated commercial demand or recurring operating income from its candidates. Until a program advances through development and reaches commercialization or a monetizing partnership, the business remains dependent on investment capital and scientific progress.
Read all positive and negative factors
Positive Factors
Negative Factors
Low Financial Leverage
Very low leverage limits interest and refinancing pressure while preserving flexibility to fund research and development. For an early-stage biotechnology company, the modest debt burden reduces fixed financial obligations, although it does not eliminate the need for future capital.
Read all positive factors
NurExone Biologic (NRX) vs. iShares MSCI Canada ETF (EWC)
Market Cap
C$50.54M
Dividend YieldN/A
Average Volume (3M)22.61K
Price to Earnings (P/E)―
Beta (1Y)-0.14
Revenue GrowthN/A
EPS Growth19.02%
CountryCA
Employees17
SectorGeneral
Sector StrengthN/A
IndustryBiotechnology
Share Statistics
EPS (TTM)-0.08
Shares Outstanding77,746,750
10 Day Avg. Volume12,904
30 Day Avg. Volume22,605
Financial Highlights & Ratios
PEG Ratio-1.72
Price to Book (P/B)13.94
Price to Sales (P/S)0.00
P/FCF Ratio-8.42
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)-0.06
Revenue Forecast (FY)N/A
NurExone Biologic Business Overview & Revenue Model
Company Description
NurExone Biologic Inc., a pharmaceutical technology company, develops a platform for biologically guided exosome-based therapies for the treatment of central nervous system injuries. Its lead product, ExoPTEN, has demonstrated strong preclinical d...
How the Company Makes Money
As a preclinical-stage biotechnology company, NurExone Biologic does not publicly report product sales from approved therapies; its business model is primarily centered on advancing its exosome-based drug candidates through research and developmen...
NurExone Biologic Financial Statement Overview
Summary
Income Statement
18
Very Negative
Balance Sheet
55
Neutral
Cash Flow
22
Negative
| Breakdown | TTM | Mar 2026 | Mar 2025 | Mar 2024 | Dec 2022 | Mar 2022 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Gross Profit | -55.08K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| EBITDA | -6.07M | -6.17M | -4.94M | -3.60M | -8.12M | -1.68M |
| Net Income | -6.31M | -6.38M | -5.04M | -3.64M | -8.17M | -1.62M |
Balance Sheet | ||||||
| Total Assets | 2.62M | 4.08M | 2.44M | 2.17M | 2.79M | 2.81M |
| Cash, Cash Equivalents and Short-Term Investments | 1.01M | 2.14M | 700.00K | 541.00K | 2.46M | 2.21M |
| Total Debt | 52.00K | 108.00K | 33.00K | 20.00K | 44.00K | 1.03M |
| Total Liabilities | 1.35M | 1.32M | 680.00K | 1.98M | 698.00K | 1.64M |
| Stockholders Equity | 1.27M | 2.76M | 1.76M | 189.00K | 2.10M | 1.17M |
Cash Flow | ||||||
| Free Cash Flow | -4.71M | -4.57M | -5.54M | -3.06M | -3.90M | -1.21M |
| Operating Cash Flow | -4.65M | -4.51M | -4.89M | -2.94M | -3.85M | -1.21M |
| Investing Cash Flow | -37.00K | -55.00K | -658.00K | -97.00K | -89.00K | 0.00 |
| Financing Cash Flow | 4.41M | 5.83M | 5.88M | 1.13M | 4.29M | 3.40M |
NurExone Biologic Technical Analysis
Positive
0.50
Price Trends
0.57
Positive
0.57
Positive
0.60
Positive
Market Momentum
0.02
Positive
54.20
Neutral
52.78
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For TSE:NRX, the sentiment is Positive. The current price of 0.5 is below the 20-day moving average (MA) of 0.64, below the 50-day MA of 0.57, and below the 200-day MA of 0.60, indicating a bullish trend. The MACD of 0.02 indicates Positive momentum. The RSI at 54.20 is Neutral, neither overbought nor oversold. The STOCH value of 52.78 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for TSE:NRX.
NurExone Biologic Peers Comparison
UnderperformOutperform
Sector (55)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
55 Neutral | $6.65B | 3.83 | -15.92% | 6.20% | 10.91% | 7.18% | |
51 Neutral | C$50.54M | -5.90 | -337.24% | ― | ― | 19.02% | |
51 Neutral | C$50.02M | -0.33 | -147.92% | ― | ― | 85.31% | |
48 Neutral | C$577.68K | 1.45 | 34.52% | ― | ― | ― | |
46 Neutral | C$29.88M | -1.75 | -360.29% | ― | ― | -33.27% | |
42 Neutral | C$13.32M | -2.43 | 92.37% | ― | ― | 16.04% | |
41 Neutral | C$39.65M | -3.57 | 57.10% | ― | ― | 48.06% |
* General Sector Average
TSE:NRX
NurExone Biologic
0.65
-0.26
-28.57%
TSE:MDNA
Medicenna Therapeutics Corp
0.39
-0.57
-59.47%
TSE:BCT
BriaCell Therapeutics
5.75
-12.45
-68.41%
TSE:HEM
Hemostemix
0.06
-0.05
-45.22%
TSE:SVA
Sernova
0.11
-0.08
-43.24%
TSE:VXL
Vaxil Bio
0.15
-0.07
-30.95%
NurExone Biologic Corporate Events
Business Operations and Strategy
NurExone Steps Up U.S. Push With Boston Life Sciences Events and Investor Campaign
Positive
Sep 18, 2026
NurExone Biologic is intensifying its U.S. presence as it advances exosome-based regenerative therapies, including its lead candidate ExoPTEN for acute spinal cord injury. The company is aligning this scientific focus with plans to build a U.S. ma...
Business Operations and StrategyShareholder MeetingsStock Split
NurExone Shareholders Back Board, Clear Path for Potential 30-for-1 Share Consolidation
Positive
Sep 16, 2026
NurExone Biologic reported that shareholders overwhelmingly approved all resolutions at its annual general and special meeting, including the re-election of the full slate of directors, reappointment of its auditor and re-approval of the omnibus e...
Business Operations and StrategyExecutive/Board ChangesFinancial DisclosuresPrivate Placements and FinancingStock Split
NurExone advances exosome programs as R&D spend rises and new financing secured
Positive
Aug 31, 2026
NurExone reported second-quarter 2026 results showing higher research and development spending of US$0.75 million, driven by advancement of its ExoPTEN program, while general and administrative expenses fell to US$0.93 million on lower professiona...
Business Operations and Strategy
NurExone to Spotlight Exosome Platform at Moody Capital Disruptive Growth Conference
Positive
Aug 28, 2026
NurExone Biologic Inc. will present at the Moody Capital Solutions 2026 Disruptive Growth Life Sciences Conference in New York, where Co-Founder and Chairman Yoram Drucker will deliver an investor presentation and hold one-on-one meetings. The co...
Business Operations and StrategyDelistings and Listing ChangesShareholder MeetingsStock Split
NurExone Seeks Shareholder Approval for Share Consolidation to Support U.S. Listing Bid
Positive
Aug 21, 2026
NurExone Biologic has called an annual general and special meeting for September 15, 2026, where shareholders will vote on a proposed consolidation of its common shares at a ratio of up to 30 pre-consolidation shares for one post-consolidation sha...
Business Operations and StrategyPrivate Placements and Financing
NurExone Raises C$1.07 Million in Private Placement to Support Regenerative Therapy Push
Positive
Aug 20, 2026
NurExone Biologic has closed a non-brokered private placement of 1,938,326 units at C$0.55 per unit, raising approximately C$1.07 million in gross proceeds, subject to final approval from the TSX Venture Exchange. The funds are earmarked for gener...
Business Operations and Strategy
NurExone Preclinical Data Bolster Neuroprotective Case for ExoPTEN in Spinal Cord Injury
Positive
Aug 14, 2026
NurExone Biologic reported new preclinical tissue-analysis data indicating that animals treated with its exosome-based candidate ExoPTEN showed significantly higher numbers of myelin-positive (MBP) cells on both sides of a traumatic spinal cord in...
Business Operations and Strategy
NurExone Strikes Exclusive U.S. GMP Exosome Manufacturing Pact with Made Scientific
Positive
Aug 12, 2026
NurExone Biologic, through its U.S. subsidiary Exo‑Top, has signed a binding memorandum of understanding with Made Scientific to establish an exclusive U.S. GMP manufacturing and commercial exosome supply partnership. The parties plan to tra...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.